Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SGRY · against 335 other Healthcare companies of similar size
Ranked #169 of 336 · scores higher than 49% of peers
Bars: peers in each 10-point band of the valuation score31 peers with a valuation score of 50–59, including SGRY · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | SGRY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 330 reported | -3.0% | 2.4% | 25% | 30% | |
| EBITDA yieldHigher is better · 331 reported | 7.5% | 4.7% | 71% | 50% | |
| Free cash flow yieldHigher is better · 176 reported | 6.2% | 0.1% | 83% | 20% | |
| Book yieldHigher is better · 328 reported | 55.7% | 29.6% | 78% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 167 | 2.2B CAD (≈$1.6B) | 56 | 44 | |
| 169 | 414.8B INR (≈$5.0B) | 55 | 73 | |
| 169 | 494.7B INR (≈$5.9B) | 55 | 70 | |
| 169 | 1.6B USD | 55 | 51 | |
| 169 | 3.0B USD | 55 | 39 | |
| 173 | 5.8B USD | 54 | 68 | |
| 174 | 21.5B DKK (≈$3.2B) | 53 | 58 | |
| 174 | 2.6B USD | 53 | 66 | |
| 174 | 5.5B USD | 53 | 43 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score